ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
New Webinar Will Explain Reimbursement Changes in Medicare’s 2026 Final Rules
Both the Medicare Physician Fee Schedule and the Hospital Outpatient Prospective Payment…
Medical Societies Renew Push for Prior Authorization Legislation
ASNC has joined more than 125 medical societies on a letter to…
ASNC Releases Payment Charts Compiling Final 2026 Rates for All Nuclear Cardiology Billing Codes
Access to the latest MPFS and HOPPS Payment Charts is available as…

